100s of titles, one news app for just $10 a month.
Dive Deeper:
Caribou's Lymphoma Candidate Shows 100% Response Rate In Early-Stage Study
Caribou Biosciences Inc (NASDAQ: CRBU) announced initial data from its ANTLER Phase 1 trial for CB-010 in relapsed or refractory B cell non-Hodgkin…
MoonLake Immunotherapeutics Begins Sonelokimab Phase 2 trial In Hidradenitis Suppurativa (HS)
MoonLake Immunotherapeutics AG (NASDAQ: MLTX) dosed first patient in the Phase 2 clinical trial evaluating sonelokimab, for patients with moderate-to-severe hidradenitis…
Lantheus Holdings Doses First Patient in Phase 2 Clinical Trial of NM-01 for NSCLC
Lantheus Holdings, Inc. (NASDAQ: LNTH) dosed first patient in a Phase 2 trial evaluating NM-01, its proprietary technetium 99m SPECT…
ACHV: First Quarter 2022 Results
By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT
One subscription that gives you access to news from hundreds of sites
New tumour-injecting gel to treat brain cancer revealed
Mahidol University has introduced biopolymer gel, a new drug delivery system, to effectively treat brain cancer patients while also reducing…
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Here's a roundup of top developments in the biotech space over the last 24 hours:
Get all your news in one place
Latest Technology news:
Barnes & Noble’s next Nook is as entry-level as e-readers come
The GlowLight 4e is bare-bones and $30 less than its predecessor.
Read news from The Economist, FT, Bloomberg and more, with one subscription
Learn More
First F-150 Lightning Retail Customer Takes Delivery In Michigan
The customer opted for an F-150 Lightning Platinum model and paid the sticker price of $90,874 for the top-of-the-range pickup.
Play it cool: This company is building a cryogenic gas station in space
ETA Space is trying to solve one of the biggest problems with space travel. It might just have a solution.
I can’t get enough of Spotify’s depraved, hyper-specific playlists
The addictive subreddit r/weirdspotifyplaylists focuses on the stranger user-generated playlists one can find on the streaming service.
Record 2021 Revenues Bump Tesla Up 35 Places On The Fortune 500 List
It has jumped from spot 100 to 65 after its profits went up more than 600 percent last year.
From analysis to good news, read the world’s best news in one place
Zotac’s VR backpack straps an entire gaming PC to your body
This is actually the fourth-generation of its VR Go backpack that untethers your from your desk for any VR application.
Tesla May Follow Through With Musk's Drive-In Theater Supercharger
Musk has talked about the potential for a drive-in diner/theater as part of a Supercharger station. Now, the company has…

Acutus Medical Completes Patient Enrolment In AcQForce Flutter IDE Trial

By Ragothaman Srinivasan

Acutus Medical (NASDAQ:AFIB) completed patient enrollment in the AcQForce Flutter Investigational Device Exemption (IDE) clinical trial.

The trial was designed to evaluate the safety and efficacy of the AcQBlate FORCE sensing ablation catheter and system in the treatment of right atrial typical flutter.

Acutus Medical has enrolled 110 patients at 21 sites globally.

David Roman, interim Chief Executive Officer, said, ”Completing enrollment in the AcQForce Flutter trial represents a significant advancement in our journey to enter the United States with a therapeutic technology for the treatment of atrial flutter. Acutus has a strong history of partnering with physicians to bring innovative technology to the market to treat atrial arrhythmias.”

Acutus Medical is trading down 4 percent at $0.91

What is inkl?
The world’s most important news, from 100+ trusted global sources, in one place.
Morning Edition
Your daily
news overview

Morning Edition ensures you start your day well informed.

No paywalls, no clickbait, no ads
Enjoy beautiful reading

Content is only half the story. The world's best news experience is free from distraction: ad-free, clickbait-free, and beautifully designed.

Expert Curation
The news you need to know

Stories are ranked by proprietary algorithms based on importance and curated by real news journalists to ensure that you receive the most important stories as they break.

Dive Deeper:
Caribou's Lymphoma Candidate Shows 100% Response Rate In Early-Stage Study
Caribou Biosciences Inc (NASDAQ: CRBU) announced initial data from its ANTLER Phase 1 trial for CB-010 in relapsed or refractory B cell non-Hodgkin…
MoonLake Immunotherapeutics Begins Sonelokimab Phase 2 trial In Hidradenitis Suppurativa (HS)
MoonLake Immunotherapeutics AG (NASDAQ: MLTX) dosed first patient in the Phase 2 clinical trial evaluating sonelokimab, for patients with moderate-to-severe hidradenitis…
Lantheus Holdings Doses First Patient in Phase 2 Clinical Trial of NM-01 for NSCLC
Lantheus Holdings, Inc. (NASDAQ: LNTH) dosed first patient in a Phase 2 trial evaluating NM-01, its proprietary technetium 99m SPECT…
ACHV: First Quarter 2022 Results
By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT
One subscription that gives you access to news from hundreds of sites
New tumour-injecting gel to treat brain cancer revealed
Mahidol University has introduced biopolymer gel, a new drug delivery system, to effectively treat brain cancer patients while also reducing…
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Here's a roundup of top developments in the biotech space over the last 24 hours:
Get all your news in one place